Oct 30, 2017 - This screen will help you to get into momentum stocks that are storming ahead. Highlighted stocks include: IONS, OSB and SKX.
Nov 06, 2017 - Ionis Pharmaceuticals, Inc. (IONS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Nov 07, 2017 - Ionis Pharmaceutical (IONS) reported mixed quarter with earnings beating estimates while revenues missing it.
Nov 27, 2017 - Tesla (TSLA) completes installation of the lithium-ion battery in South Australia within 55 days of signing the grid connection deal.
Dec 20, 2017 - A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
Feb 08, 2018 - Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.
Feb 22, 2018 - Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Feb 23, 2018 - Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
Apr 02, 2018 - Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Apr 02, 2018 - Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.